pharmaphorum

NOVEMBER 20, 2020

Havas Lynx Group’s 2020 white paper provides a blueprint for pharma brands to inject meaning into their media. The latter is the subject of our 2020 white paper, Media Means Business. COVID-19 has left us more reliant on media than ever – both the pharma industry and society as a whole. What do we mean by ‘media’?

98

98

pharmaphorum

NOVEMBER 9, 2021

The pandemic’s first effects on pharma sales were swift and immediate, as lockdowns were put in place and doctors did everything they could to avoid unnecessary face-to-face contact with patients and representatives. This white paper explains how to adjust to it. The industry faces the dawn of a new age in sales coaching.

Communication 97

Communication 97

PharmaTech

OCTOBER 22, 2023

Sponsors and CROs looking to tackle these challenges and reduce the burden on participants and sites should explore the potential of digital solutions, particularly electronic informed consent (eConsent) and electronic patient-reported outcomes (ePRO). Unlock the content to read the full white paper.

40

40

PharmaTech

JUNE 27, 2022

An accessible, intuitive digital clinical platform that connects sponsors, sites & patients, and replaces burdensome paper forms and physical visits with electronic consents (eConsent), electronic Clinical Outcome Assessments (eCOA’s), and remote visits (TeleVisits). Download the White Paper now to learn how.

40

40

pharmaphorum

OCTOBER 5, 2021

Since 2019, pharmaceutical companies have been speeding to integrate digital channels and processes into their marketing efforts and patient outreach, to prepare for the wave of digitisation in the healthcare industry. Read: Transform patient experience with intelligent hyper-personalisation in full.

Pharmaceutical Companies 118

Pharmaceutical Companies Pharmaceutical Companies 118

pharmaphorum

OCTOBER 4, 2021

COVID-19 forced an unprecedented shift towards the virtual delivery of healthcare, suddenly compelling doctors increasingly to use digital means to care for their patients. As healthcare resources and delivery were prioritised, there was also a massive and ongoing impact on growing waiting lists and time-lags for diagnosis and treatment.

Communication 72

Communication 72

PharmaTech

JUNE 27, 2022

Patient recruitment, retention, diversity, & safety are all factors driving the need for radical innovation in clinical research. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now.

40

40

pharmaphorum

FEBRUARY 15, 2021

The overall aim of the alliance – which will see Healthware work alongside the NCI’s Pascale Hospital – is to develop digital health tools that will deliver “more precise and accessible treatments to patients”, said the partners in a statement.

Communication 95

Communication Hospitals 95

PharmaState Academy

MARCH 12, 2023

Preamble Why this White Paper? A white paper (sometimes called as whitepaper) is an information document issued by an organization to highlight the solution to a problem the functionality of a solution, good, or service. The ultimate objective of brand promotion should be the patients’ health outcome.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Hospitals Communication 52

Pharma Marketing Network

JULY 19, 2023

This information could be valuable to potential patients who are considering taking the drug, and it could help the company attract new leads. For example, a pharmaceutical company could create a white paper about a particular medical condition.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

AUGUST 5, 2021

Health Union’s white paper, Beyond the Treatment, Making the HCP-Patient Relationship Work: A Study Uncovering the Patient Perspective , explores those relationships in detail. Furthermore, that thought process can be truly reductive of the hurdles patients may overcome to find a treatment plan that works for them.

Communication 98

Communication 98

pharmaphorum

SEPTEMBER 1, 2021

The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians implemented during the acute phase of the pandemic, with a focus on the way in which treatment strategies were altered.

112

112

pharmaphorum

FEBRUARY 10, 2021

The recommendations for the Country’s pathway towards DTx are captured in the White Paper “Digital Therapeutics, an Opportunity for Italy” The official journal of the Smith Kline Foundation, Tendenze Nuove , published the White Paper “ Digital Therapeutics, an Opportunity for Italy ” on 13 January 2021.

Documentation 52

Documentation 52

Pharmaceutical Technology

DECEMBER 8, 2022

Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. It is created by taking T cells from the patient’s blood and then engineered in the laboratory to express chimeric antigen receptors. . Optimise your cell therapy process: a guide to cell thawing.

Communication 122

Communication Immunity Immunization Hospitals 122

Drug Channels

FEBRUARY 23, 2021

In this issue: Payers confess: Patients lose from copay accumulators Humana joins the Express Scripts GPO Hospitals vs. PBMs over specialty pharmacy white bagging Let’s all follow the Buy-and-Bill Dollar! Copay Accumulators: Shifting Cost Of Care From Plan Sponsors To Patients? , The battle for specialty drug margin rages on.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Independent Pharmacies Online Pharmacies 52

Pharmaceutical Technology

JANUARY 17, 2023

It could be used for T-Cell Acute Lymphoblastic Leukaemia (T-ALL) treatment in patients for whom bone marrow transplantation and chemotherapy failed to work. Dr Alvarez-Vallina said: “It is necessary to develop strategies addressed to very specific targets for each disease and adapted for each patient. STAb-T therapy is on this path.”.

Hospitals 110

Hospitals Chemotherapy Communication Immunity 110

Pharmaceutical Technology

DECEMBER 21, 2022

The vaccine manufacturing facility will also offer National Health Service (NHS) patients access to the company’s Covid-19 vaccines that can provide protection against various variants. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Vaccines 140

Vaccines Communication 140

pharmaphorum

MARCH 10, 2021

A new focus on “place” and the introduction of medicines registers are among the proposals in a new government white paper on the future of NHS England. This is where the bulk of healthcare will be experienced by patients. Very few decisions will be taken at that level. Medicines registries. Opportunities abound.

Documentation 59

Documentation Diabetes 59

Pharmaceutical Technology

FEBRUARY 16, 2023

The MOS platform enables translational research on micro-tumours derived from patients with new capabilities. It enables quick evaluation of a patient tumour response to a range of cancer drug modalities within 14 days of obtaining harvested samples of tumour cells.

Drug Development 96

Drug Development Communication 96

Pharmaceutical Technology

MARCH 8, 2023

The multi-year collaboration aims to develop new technologies which will help in improving clinical outcomes for patients. We are delighted to be partnering with the CAR T pioneers at Penn and believe that combining our expertise in science and technology will help bring the next generation of cell therapies to patients faster.”

Communication 97

Communication 97

Pharmaceutical Technology

MARCH 10, 2023

The representative expected the facility to open more treatment opportunities for UK citizens saying, “It will help give patients quick access to the latest treatments by increasing the number of UK patients with incurable diseases who are able to take part in clinical trials and bring new treatments into the NHS faster.”

Communication 105

Communication 105

Pharmaceutical Technology

NOVEMBER 29, 2022

With a shared mission of making cell therapies available to solid tumour patients, the capabilities of Neogene in TCR-T discovery, development and production will bolster the goal of AstraZeneca to transform patient outcomes. The takeover will offer AstraZeneca access to TCR-Ts, which possess the potential for fighting solid tumours.

Communication 111

Communication 111

Pharmaceutical Technology

FEBRUARY 9, 2023

ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients. Our BindeR and SpliceR platform technologies have the potential to advance therapeutics for undruggable cancer targets, and we believe this collaboration will accelerate the discovery of new treatments for patients.”

Communication 96

Communication 96

Pharmaceutical Technology

DECEMBER 23, 2022

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. Optimise your cell therapy process: a guide to cell thawing.

Diabetes 131

Diabetes Communication 131

pharmaphorum

AUGUST 24, 2022

It was compared in the study to an already-available free app – TMSOFT’s White Noise Lite – which is described by the researchers as “a popular self-help passive sound therapy app.” The results have just been published in the journal Frontiers in Neurology.

52

52

Pharmaceutical Technology

MARCH 20, 2023

With this collaboration, we want to develop mRNA vaccine product candidates with the potential to improve the lives of patients who suffer from certain autoimmune diseases and allergies.” RVAC Medicines CEO Dr Sean Fu said: “We are excited to begin this collaboration with Dr Weissman, a pioneer in the field of mRNA vaccines and therapeutics.

Vaccines 98

Vaccines Immunity Immunization Communication 98

pharmaphorum

APRIL 11, 2022

“The industry has concerns regarding the use of regulatory tools designed for medicines authorisation being applied to address availability issues that are within the remit of member states,” says the white paper. . — EFPIA (@EFPIA) April 11, 2022.

Documentation 52

Documentation Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Free Whitepaper Optimise your cell therapy process: a guide to cell thawing Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.

Vaccines 115

Vaccines Communication 115

Pharmaceutical Technology

DECEMBER 12, 2022

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Most importantly, this collaboration is focused on accelerating access for patients in need.”.

Communication 105

Communication 105

Pharmaceutical Technology

JANUARY 5, 2023

Prevail and Capsida are committed to developing highly effective and safe gene therapies that have the potential to be transformative for patients living with serious CNS diseases.”. According to the deal, Capsida will get $55m, comprising an upfront payment and a commitment to participate in its next funding round.

Communication 95

Communication 95

Putting Patients First Blog

FEBRUARY 5, 2024

A Reminder of NHC Benefits February 5, 2024 By: Bob Scott, Director, Member Services The National Health Council (NHC) brings diverse organizations together to forge consensus, drive patient-centered health policy, and provide a united voice for the more than 160 million people with chronic diseases and disabilities and their family caregivers.

Documentation 59

Documentation Communication 59

Express Pharma

DECEMBER 26, 2023

Informa markets informed that a white paper report on the key takeaways is being prepared. This remarkable growth is driven by cutting-edge technology, breakthrough drugs, and a patient-centric focus, positioning India as a major player in the global pharma landscape.

Pharmaceutical Manufacturing 96

Pharmaceutical Manufacturing 96

Pharmaceutical Technology

MARCH 28, 2023

This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure.

Diabetes 94

Diabetes Communication 94

Pharmaceutical Technology

DECEMBER 18, 2022

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. Optimise your cell therapy process: a guide to cell thawing.

Vaccines 121

Vaccines Communication 121

Pharmaceutical Technology

JANUARY 27, 2023

The chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel has been recommended for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) in adult patients who have previously received two or more lines of systemic therapy.

Communication 59

Communication Immunity Immunization 59

Pharmaceutical Technology

DECEMBER 5, 2022

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. Optimise your cell therapy process: a guide to cell thawing.

Vaccines 98

Vaccines Communication Immunity Immunization 98

Pharmaceutical Technology

JANUARY 10, 2023

Under the deal terms, Boehringer Ingelheim will be responsible for providing patient-derived TCR data to fuel the target discovery efforts of 3T Biosciences for identifying antigens leveraging its 3T TRACE discovery platform. The company will receive an undisclosed upfront payment and research and development support.

Immunity 52

Immunity Immunization Compounding Communication 52